Compare Johnson & Johnson (JNJ) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Johnson & Johnson trades at $248.49 (market cap $598.96B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $60.09 (market cap $77.37B). The key difference: Johnson & Johnson is far larger — about 7.7× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| JNJ | MDLZ | |
|---|---|---|
Market Cap | $598.96B | $77.37B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Staples |
52-Week High | $267.24 | $70.75 |
52-Week Low | $164.36 | $51.51 |
Enterprise Value | $631.90B | $97.46B |
Dividend Yield | 2.15% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Mondelez International (MDLZ) trades at $60.15, down 1.39% today, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 28.77% gross margins and has beaten earnings estimates for three consecutive quarters. Recent corporate developments include a new CFO appointment and continued dividend payments, while analyst consensus remains strongly positive with a $68 price target representing 13% upside potential.
The outlook for MDLZ appears favorable with consistent earnings beats and solid dividend yield, though investors face risks from margin compression and commodity price volatility. Wall Street's bullish stance is supported by the company's market leadership in snacks and innovation pipeline, but execution on volume growth remains critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
